For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com

All subjects will have locally advanced or metastatic solid tumors

For Part 2 (Cohort Expansion):

* Tumor types will be restricted to clear cell renal cell carcinoma (ccRCC), non-small cell lung cancer (NSCLC), and melanoma

At least 1 lesion with measurable disease

Only subjects with tumor samples that are PD-L1 positive or negative are eligible

Safety Study of IL-21/Anti-PD-1 Combination in the Treatment of Solid Tumors